Friday 18 October 2013
Responding to new NICE draft guidance recommending enzalutamide as an option for treating hormone relapsed metastatic prostate cancer in adults:
Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, London, said:
“Advanced prostate cancer is very difficult to treat, and it’s taken a coordinated effort to finally bring new drugs into the pipeline, after decades where there were no options once old-style hormone treatment stopped working.
“What we’re seeing now is an unprecedented period of success for prostate cancer research, with four new drugs shown to extend life in major clinical trials in just two years, and several others showing promise. It truly is a golden age for prostate cancer drug discovery and development.”
Notes to editors
For more information contact the ICR press office on 020 7153 5312 / [email protected].
For enquiries out of hours, please contact Claire Bithell, ICR’s Head of Media Relations, on 07969 082 520.
Related stories
Making a difference in prostate cancer - The ICR Research Blog
Men with incurable prostate cancer living for twice as long as decade ago
Prostate cancer drug shown to extend life and improve quality of life